Pregnant and Postpartum Women with Atypical Glandular Cells: Follow-up and Evaluation for High-Risk HPV
Cancer Research Journal
Volume 1, Issue 4, November 2013, Pages: 31-36
Received: Oct. 15, 2013; Published: Nov. 10, 2013
Views 2582      Downloads 181
Author
Intisar Salim Pity, Dept of Pathology, Faculty of Medical Science, UOD, Duhok, Iraq
Article Tools
PDF
Follow on us
Abstract
Objectives: The study was an attempt: to find out the prevalence of atypical glandular cells of undetermined significance (AGC) in cervicovaginal smears of pregnant and postpartum women in Duhok-Iraq; follow up these women to investigate the underlying pathology and to test for high-risk HPV (HR-HPV). Methods: From May 2005 to June 2013, all Pap smears of pregnant and postpartum women were analyzed and women with AGC cytology were enrolled in the study. One hundred and fifty two women, for whom follow up was possible, were subjected to colposcopic directed cytology and/or histology for at least 48 months from the initial reading. Their results were comprehensively evaluated, and HR-HPV DNA testing was performed by conventional PCR in 56 cases. Results: Overall, AGC cytology formed 6.7% of all pregnant and postpartum women’s Pap smears and 29.6% were at risk for neoplastic epithelial lesions (AGC and premalignant lesions). The diagnosis of ≥ low squamous intraepithelial lesion (LSIL) was observed in 14.5% of cases among whom significantly high frequency of HR-HPV DNA was noted compared with those having persistent AGC or negative atypia (NILM). Conclusions: Identical to non-pregnant women, pregnant and postpartum women with AGC cytology are at risk of harboring premalignant and malignant (squamous or glandular) lesions, and testing of AGC cytologic specimens for HR-HPV might help predict neoplastic cases but not to distinguish malignant from premalignant lesions.
Keywords
Pap smear, AGC, Follow Up, High-risk HPV-DNA
To cite this article
Intisar Salim Pity, Pregnant and Postpartum Women with Atypical Glandular Cells: Follow-up and Evaluation for High-Risk HPV, Cancer Research Journal. Vol. 1, No. 4, 2013, pp. 31-36. doi: 10.11648/j.crj.20130104.11
References
[1]
TC Jr Wright, JT Cox, LS Massad, LB Twiggs, EJ Wilkinson. 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002;287:2120-9.
[2]
D Solomon, D Davey, R Kurman. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114–9.
[3]
KF Tam, AN Cheung, E Szeto, HY Ngan. Atypical glandular cells diagnosed during pregnancy and the postpartum period: a retrospective analysis. 2011 Apr;155(2):213-6.
[4]
DC Chhieng, S Gallaspy, H Yang, J Roberson, I Eltoum. Women with atypical glandular cells. A long-term follow-up study in a high-risk population. Am J Clin Pathol. 2004;122:575-9.
[5]
TC Jr Wright, LS Massad, CJ Dunton, M Spitzer, EJ Wilkinson, D Solomon; 2006 ASCCP-Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis. 2007;11(4):201-22.
[6]
MK Frey, D Gupta. Evaluation of Women with Atypical Glandular Cells on Cervical Cytology. Gynecologic oncology. 2011;36(9):23-29.
[7]
CV Gonçalves, G Duarte, JSD da Costa, AC Marcolin, MS Bianchi VMS, D Dias, et al. Diagnosis and treatment of cervical cancer during pregnancy. Sao Paulo Med J. 2009;127(6):359-65.
[8]
PF Schnatz, KE Sharpless, DM O'Sullivan. Use of human papillomavirus testing in the management of atypical glandular cells. J Low Genit Tract Dis. 2009;13(2):94-101.
[9]
J Slama, P Freitag, P Dundr, J Duskova, D Fischerova, M Zikan, et al. Outcomes of pregnant patients with Pap smears classified as atypical glandular cells. Cytopathology. 2012;23(6):383-8.
[10]
IS Pity, MY Shamdeen, SA Wais. Follow up of Atypical Squamous Cell Pap Smears in Iraqi Women. APJC. 2012;13:3455-60.
[11]
C Zhao, RM Austin, J Pan, N Barr, SE Martin, A Raza, C Cobb. Clinical significance of atypical glandular cells in conventional Pap smears in a large, high-risk U.S. West Coast minority population. Acta Cytol. 2009;53(2):153-9.
[12]
PP Koonings, JH Price. Evaluation of atypical glandular cells of undetermined significance: is age important? Am J Obstet Gynecol. 2001;184(7):1457-9.
[13]
KE Sharpless, PF Schnatz, S Mandavilli, JF Greene, JI Sorosky. Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol. 2005;105(3):494-500.
[14]
DC Chhieng, P Elgert, JF Cangiarella, JM Cohen. Significance of AGUS Pap smears in pregnant and postpartum women. Acta Cytol. 2001;45(3):294-9.
[15]
S Sarkar, S Yusif, D Egan. Cervical screening during pregnancy. Ir Med J. 2006;99(9):284-5.
[16]
A de-Roda Husman, JMM Walboomers, AJC van den Brule, CJLM Meijer, PJF Snijder. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. Journal of General Virology. 1995;76:1057-62.
[17]
MV Jacobs, PJ Snijders, AJ van den Brule, TJ Helmerhorst, CJ Meijer, JM Walboomers. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol. 1997;35:791-5.
[18]
TJ Kim, HS Kim, CT Park, IS Park, SR Hong, JS Park, et al. Clinical evaluation of follow-up methods and results of atypical glandular cells of undetermined significance (AGUS) detected on cervicovaginal Pap smears. Gynecologic Oncology. 1999;73(2):292-8.
[19]
CA Chen, CY Liu, HH Chou, CY Chou, CM Hok, NF Twu, et al. The distribution and differential risks of human papillomavirus genotypes in cervical preinvasive lesions: a Taiwan cooperative oncologic group study. Int J Gynecol Cancer. 2006;16:1801-8.
[20]
D Ajit, S Gavas, S Joseph, B Rekhi, K Deodhar, S Kane. Identification of atypical glandular cells in Pap smears: Is it a hit and miss Scenario? Acta Cytologica. 2013;57:45–53.
[21]
K Kapila, SS George, A Al-Shaheen, MS Al-Ottibi, SK Pathan, ZA Sheikh, et al. Changing spectrum of squamous cell abnormalities observed on papanicolaou smears in Mubarak Al-Kabeer Hospital, Kuwait, over a 13-year period. Med Princ Pract. 2006;15(4):253-9.
[22]
S Sımavli, I Kaygusuz, S Cukur, F Aksel. Abnormal cervical cytology risk factors in the Western Black Sea Region and the importance of health insurance..TurkPatolojiDerg. 2013;24. doi: 10.5146/tjpath.2013.01193
[23]
C Wensveen, M Kagie, R Veldhuizen, C De Groot, L Denny, K Zwinderman, et al. Detection of cervical intraepithelial neoplasia in women with atypical squamous or glandular cells of undetermined significance cytology: a prospective study. Acta Obstet Gynecol Scand. 2003 Sep;82(9):883-9.
[24]
AJ Meath, ME Carley, TO Wilson. Atypical glandular cells of undetermined significance. Review of final histologic diagnoses. J Reprod Med. 2002;47(4):249-52.
[25]
CS Geier, M Wilson, W Creasman. Clinical evaluation of atypical glandular cells of undetermined significance. Am J Obstet Gynecol. 2001;184(2):64-9.
[26]
SF Derchain, SH Rabelo-Santos, LO Sarian, LC Zeferino , ER de Oliveira Zambeli , MC do Amaral Westin, et al. Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears. Gynecol Oncol. 2004;95(3):618-23.
[27]
C Zhao, A Florea, RM Austin. Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. Arch Pathol Lab Med. 2010;134(1):103-8.
[28]
SH Rabelo-Santos, SF Derchain, LL Villa, MC Costa, LO Sarian, MC do Amaral Westin , et al. Human papillomavirus-specific genotypes in cervical lesions of women referred for smears with atypical glandular cells or adenocarcinoma in situ. Int J Gynecol Pathol. 2009;28(3):272-8.
[29]
SB Namugenyi, MJ Balsan, SN Glick, JA Jordan. Prevalence and genotype distribution of human papillomavirus in cytology specimens containing atypical glandular cells: A case-control study. J Clin Virol. 2013 Oct;58(2):432-6.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186